Form 8-K · Current Report · Filed 2026-02-12
BridgeBio Announces Positive Phase 3 Results for Oral Infigratinib in Achondroplasia
BridgeBio Pharma, Inc. reported positive topline results from the Phase 3 PROPEL 3 study for oral infigratinib, showing statistically significant improvements in annualized height velocity and body proportionality in children with achondroplasia. The company plans to submit a New Drug Application and Marketing Authorization Application in the second half of 2026. Additionally, BridgeBio intends to accelerate the development of infigratinib for hypochondroplasia.
- Filer
- BridgeBio Pharma Inc. BBIO · NASDAQ
- Filed
- Accession
- 0001140361-26-004995
- CIK
- 0001743881
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$73.33
Next session
+2.6%
Since filing
+9.2%
Latest close
$80.09
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BBIO reporting the same item, with the next session's move:
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Never miss another BBIO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.